Market Overview

UPDATE: Valeant Pharmaceuticals Posts Higher Q2 Profit


Valeant Pharmaceuticals International (NYSE: VRX) reported a rise in its second-quarter profit.

The Laval, Canada-based company reported a quarterly profit of $125.8 million, or $0.37 per share, versus a year-ago profit of $10.8 million, or $0.03 per share. Excluding certain items, its cash earnings surged to $1.91 per share versus $1.34 per share.

Its revenue climbed 86% to $2.04 billion. However, analysts were expecting earnings of $1.90 per share on revenue of $2.04 billion.

Valeant's same store organic product sales rose 4% in the quarter. Excluding the impact of generics, its same store organic product sales surged 10%. Same store organic sales surged 17% in Asia, while same store sales climbed 13% in emerging markets in Europe.

"Valeant once again delivered strong quarterly results and, as expected, organic growth has accelerated from the first quarter," said J. Michael Pearson, chairman and chief executive officer.

Valeant shares fell 0.74% to $124.90 in pre-market trading.


Related Articles (VRX)

View Comments and Join the Discussion!

Posted-In: profitEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at